Bristol-Myers Squibb has entered two agreements with ViiV Healthcare to divest its pipeline of investigational HIV medicines in various stages of development, for $350 million upfront with potential development and regulatory milestone payments of as much as $518 million for clinical assets and as much as $587 million for discovery and preclinical programs. The divestiture is expected to be completed in 1H16, subject to customary closing conditions.   Once products are approved and commerciali...